GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.

Glycart Biotechnology AG, Genentech Inc, F Hoffmann-La Roche Ltd, Biogen Idec Inc and Chugai Pharmaceutical Co Ltd are developing GA-101, a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb, for the potential treatment of B-cell malignancies. Compared with classic type I CD20 antibodies (eg, rituximab), GA-101 binds with high affinity to the CD20 type II epitope, resulting in the induction of antibody-dependent cytotoxicity that is 5- to 100-fold greater than observed upon treatment with rituximab. GA-101 also exhibits superior direct cell killing properties than rituximab. In preclinical studies, GA-101 was significantly more potent and effective in depleting B-cells than rituximab, and induced dose-dependent antitumor activity, complete tumor regression and improved long-term survival in xenograft mouse models of B-cell malignancy. In a phase I/II clinical trial, GA-101 had a similar safety profile to rituximab, and exhibited promising efficacy in patients with relapsed/refractory CD20-positive lymphoid malignancies. At the time of publication, phase I/II trials for GA-101 were ongoing in B-cell malignancies. Based on preclinical and preliminary clinical data, GA-101 appears to be a promising therapeutic agent for CD20-positive B-cell lymphoid malignances, including non-Hodgkin lymphomas and chronic lymphocytic leukemia.
AuthorsTadeusz Robak
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 10 Issue 6 Pg. 588-96 (Jun 2009) ISSN: 2040-3429 [Electronic] England
PMID19513948 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20
  • Antineoplastic Agents
  • obinutuzumab
  • Animals
  • Antibodies, Monoclonal (immunology, pharmacology, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20 (immunology)
  • Antineoplastic Agents (immunology, pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation, Preclinical
  • Glycosylation
  • Humans
  • Leukemia, B-Cell (drug therapy, immunology)
  • Lymphoma, B-Cell (drug therapy, immunology)
  • Mice
  • Patents as Topic
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: